According to a research report this morning, Piper Jaffray initiated an Overweight rating and a $10 PT on Supernus Pharmaceuticals SUPN as the up-and-coming pharmaceutical company introduced two impressive Central Nervous System therapies.
Piper Jaffray explained, “Supernus is an emerging specialty pharmaceutical company that is leveraging its well-established expertise in extended- and modified-release drug delivery technologies to develop and commercialize next-generation oral therapies for the treatment of a variety of diseases of the central nervous system (CNS). We could see two FDAapproved extended-release (ER) therapies, namely ER topiramate formulation SPN-538 and ER oxcarbazepine formulation SPN-804, for the treatment of epilepsy before the end of 2012.”
Supernus Pharmaceuiticals closed Friday at $5.94.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in